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Prediction of CYP2D6 phenotype from genotype
across world populations
Andrea Gaedigk, PhD1,2, Katrin Sangkuhl, PhD3, Michelle Whirl-Carrillo, PhD3, Teri Klein, PhD3
and J. Steven Leeder, PharmD, PhD1,2
Purpose: Owing to its highly polymorphic nature and major contribution to the metabolism and bioactivation of numerous clinically
used drugs, CYP2D6 is one of the most extensively studied drugmetabolizing enzymes and pharmacogenes. CYP2D6 alleles confer
no, decreased, normal, or increased activity and cause a wide range
of activity among individuals and between populations. However,
there is no standard approach to translate diplotypes into predicted
phenotype.
Methods: We exploited CYP2D6 allele-frequency data that have
been compiled for Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (>60,000 subjects, 173 reports) in order
to estimate genotype-predicted phenotype status across major world
populations based on activity score (AS) assignments.
Results: Allele frequencies vary considerably across the major ethnic
groups predicting poor metabolizer status (AS = 0) between 0.4 and

INTRODUCTION

CYP2D6 is a member of the cytochrome P450 gene superfamily, which constitutes many important phase I drug metabolizing enzymes and contributes to the metabolism of up to 25%
of clinically used drugs.1,2 As reviewed by He et al.,3 CYP2D6 is
the predominant pathway for the elimination or bioactivation
of many centrally acting drugs, including tricyclic antidepressants, serotonin-selective reuptake inhibitors, opioids, and antiemetics, but also antiarrythmics, β-blockers, antihistamines,
and antiviral agents. In addition, CYP2D6 also plays a role in
the metabolism of drugs of abuse and has been shown to bioactivate a number of procarcinogens and neurotoxins.
The CYP2D6 gene is located on Chr22q13.1 in close proximity to two nonfunctional pseudogenes, CYP2D7 and CYP2D8,
and has been extensively studied after it was first described in
1989.4 To date, more than 100 allelic variants, not counting subvariants, have been defined by the Human Cytochrome P450
(CYP) Allele Nomenclature Database at http://www.cypalleles.
ki.se/.5 Sequence and structural variations give rise to alleles
conferring no, decreased, normal, or increased function, leading to a wide range of enzyme activity among individuals and
populations.3,6 On one end of the extreme are the so-called poor
metabolizers, i.e., individuals with two nonfunctional alleles

5.4% across world populations. The prevalence of genotypic intermediate (AS = 0.5) and normal (AS = 1, 1.5, or 2) metabolizers ranges
between 0.4 and 11% and between 67 and 90%, respectively. Finally,
1 to 21% of subjects (AS >2) are predicted to have ultrarapid metabolizer status.
Conclusions: This comprehensive study summarizes allele frequencies, diplotypes, and predicted phenotype across major populations,
providing a rich data resource for clinicians and researchers. Challenges of phenotype prediction from genotype data are highlighted
and discussed.
Genet Med advance online publication 7 July 2016
Key Words: Clinical Pharmacogenetics Implementation
Consortium; CYP2D6; genotype; phenotype; world populations

who are unable to metabolize or bioactivate drugs through the
CYP2D6 pathway. On the other end of the extreme are ultrarapid metabolizers who carry at least one increased function
allele (i.e., two or more copies of a functional allele on one
chromosome) in addition to a normal-function allele. These
two metabolizer groups are at the highest risk for experiencing
dose-related adverse events or treatment failure, depending on
the particular substrate involved.
CYP2D6 allele frequencies have been shown to vary substantially among world populations.7,8 Some allelic variants
are present across populations at similar frequencies, whereas
others are observed at vastly different frequencies or have only
been detected in a certain ethnic group. Polymorphic expression of CYP2D6 is the most important single factor impacting
variable activity within and among populations.
The Clinical Pharmacogenetics Implementation Consortium
(CPIC) develops guidelines that enable the translation of genetic
laboratory test results into actionable prescribing decisions for
specific drugs (https://www.pharmgkb.org/page/cpic and https://
cpicpgx.org).9 Since its inception in 2009, 22 guidelines and
updates have been published, including three involving CYP2D6
(CYP2D6/codeine;10,11 CYP2D6 and CYP2C19/tricyclic antidepressants;12 and CYP2D6 and CYP2C19/ selective serotonin reuptake inhibitors 13). In the supplemental materials of the CYP2D6
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guidelines, allele frequencies across populations have been systematically captured and updated with each new guideline or
update. To our knowledge, this is the most comprehensive and
up-to-date resource for CYP2D6 allele-frequency information. It
is freely available through the PharmGKB at http://www.pharmgkb.org/download.action?filename=CYP2D6_Frequency_
Table_and_Legend_R3.pdf.
For this report, we have updated the allele frequency in this
table to include the most recent publications describing allele
frequencies, calculated diplotype frequencies for each study,
and translated diplotypes into phenotype based on activity
score (AS).14 The prevalence of genetically predicted phenotypes, referred to as genetic poor, intermediate, normal, and
ultrarapid metabolizers (gPM, gIM, gNM, and gUM, respectively) are shown for each study and major populations.

MATERIALS AND METHODS
Literature review and allele-frequency tabulation

The PubMed database (1995–2015) was searched using the following criteria: (CYP2D6 or 2D6 or cytochrome P4502D6) AND
(genotype OR allele OR frequency OR minor allele OR variant
OR ethnic OR race OR racial OR ethnicity) with filter limits set
to retrieve “full -text” and “English” literature. Reports were also
identified from citations by others or review articles. Studies
were included if (i) the ethnicity of the population was clearly
indicated, (ii) either allele frequencies or genotype frequencies
were reported, (iii) the method by which the genes were genotyped was indicated, (iv) the sample population consisted of ≥50
individuals with a few exceptions (e.g., smaller cohorts that were
part of larger studies), and (v) the study represented an original publication. A few studies were excluded owing to apparent
technical shortcomings or flaws in the interpretation of singlenucleotide polymorphism (SNP) data for allele assignment. For
all included studies, the first author, year of publication, and
PubMed identification or doi number and allele frequencies are
provided in Supplementary Table S1 online.
Reports were organized by worldwide race/ethnic designations according to the Human Genome Diversity Project–Centre
d’Etude du Polymorphisme Humain15,16 (Africa, Americas, East
Asia, Europe, Middle East, Oceania, and South Central Asia), with
the exception that African Americans were listed separately from
Africans. Additional population information (e.g., Caucasian,
Chinese, Spanish, geographic region, and city of enrollment) and
study subjects’ health status (i.e., whether they were healthy or
patients) were also captured. A report on an Ashkenazi Jewish
population is shown separately. Within major ethnicities, reports
were sorted by “population” and year of publication.
Nomenclature and terms

Star (*) allele designations were assigned according to the Human
Cytochrome P450 (CYP) Allele Nomenclature Database at
http://www.cypalleles.ki.se/5 and alleles were tabulated as designated in each report; for sequencing studies, alleles not listed as
being present were assigned a frequency of 0%. Allele frequencies were determined by counts. For each major ethnicity, the
70
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average frequency and range (minimum and maximum) was
determined for each allele (Supplementary Table S1 online,
yellow shading). The frequency of the CYP2D6*1 reference
allele was calculated as 100 minus the sum of variants for a subset of reports that describe allele frequencies for the most common alleles found in a particular ethnic group (Supplementary
Table S1 online, blue shading). Studies not describing *2 or few
allelic variants (e.g., *4 and *5 only or *10 only) were omitted to
maximize accuracy of CYP2D6*1 estimation.
To describe functionality of alleles and phenotype status, we adhered to the terms “no,” “decreased,” “normal,” and
“increased” function alleles and poor (PM), intermediate (IM),
normal (NM), and ultrarapid (UM) metabolizers, respectively.
These terms were determined by CPIC in an effort to standardize terms for reporting of clinical pharmacogenetic test results
(https://cpicpgx.org/resources/term-standardization/).
Translation of genotype into phenotype

Because there is sparse or no information for many allelic variants in terms of frequency and/or functionality, a subset of the
most common alleles was selected for phenotype prediction
(Supplementary Table S2 online). This selection was complemented by a small number of less common or rare alleles for
which multiple reports were available (African, *45 or *46; East
Asia, *44 and *49; multiple, *36; Africa, *40, *42; multiple, *43;
Africa and Europe, *56). Alleles were grouped according to
their perceived functionality; the values in parentheses indicate
respective values assigned to an allele to calculate the AS14,17 of
a diplotype: no-function (0) alleles (*3, *4, *4xN,*5, *6, *7, *8,
*11, *12, *36, *40, *42, *56), decreased-function (0.5) alleles (*9,
*10, *17, *29, *41, *44, *49), normal-function (1) alleles (*2, *35,
*43, *45), and increased-function (2) alleles (*1xN, *2xN).
Studies for which CYP2D6*1 was calculated (i.e., those
reporting CYP2D6*2, *41, and other commonly tested alleles)
are shaded in gray in Supplementary Table S2 online (note
that CYP2D6*1 calculations in Supplementary Table S1 online
included studies (shaded in blue) that did not distinguish
between CYP2D6*2 and *41). Next, sums of no-function (0),
decreased-function (0.5), normal-function (1), and increasedfunction (2) alleles were calculated (Supplementary Table S2
online, columns AL-AR), unless there were sparse or no data
(e.g., for the report by Gaedigk et al., row 8, no sums are shown
because this article reports only on CYP2D6*42). For normalfunction alleles, the frequency of CYP2D6*1 was calculated as
100 minus the sum of all other alleles (column AQ) and added
to the sum of frequencies of CYP2D6*2, *35, and *4 (column
AN) for a total of normal-function alleles (column AR). Allele
frequencies in Figure 1 were generated from data presented in
columns AL to AR of Supplementary Table S2 online.
Next, frequencies of diplotypes giving rise to AS were calculated using the Hardy-Weinberg equation 1 = p2 + q2 + r2 + s2 +
2pq + 2pr + 2ps + 2qr + 2qs + 2rs as shown in Supplementary
Table S3 online. Frequencies predicted for each AS are summarized in Supplementary Table S2 online columns AT to BC.
Columns BF to BL and BN to BW in Supplementary Table S2
Volume 19 | Number 1 | January 2017 | Genetics in medicine
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Figure 1 Comparison of selected allele frequencies across world
populations. Allele frequencies differ considerably between populations,
as demonstrated on selected allelic variants. Frequencies were calculated
from all studies (Supplementary Table S2 online; CYP2D6*2xN (column
L), CYP2D6*4 (column Y); CYP2D6*5 (column AA); CYP2D6*10 (column R),
and CYP2D6*17 (column S)).

online (shaded in gray) contain only data for the studies reporting minimum genotype data (*2 and a minimum of no-function (*3, *4, *5) and decreased-function (*10, *41) alleles). AS
frequencies for phenotype estimates were obtained from this
subset of data.
Standard deviations (SD) for the average, median, and range
(minimum and maximum) were determined for each allele
(Supplementary Table S2 online, shaded in yellow).

RESULTS
Literature review and allele-frequency tabulation

The most recent CYP2D6 allele-frequency table, published by
CPIC13 (PharmGKB Knowledge Base at https://www.pharmgkb.org/guideline/PA166127636 and linked to the Human
Cytochrome P450 (CYP) Allele Nomenclature Database at
http://www.cypalleles.ki.se/), was updated to include reports
published by 7 December 2015. Allele frequencies from a
total of 177 reports were tabulated, representing approximately 60,000 unrelated subjects. Several studies yielded two
or more entries (e.g., multiple ethnic groups and populations
from different geographical regions), for a total number of
263 entries. Some study populations or subsets of subjects
may have been reported more than once, especially when
additional genotyping was performed in subsequent studies
(Supplementary Table S1 online). In a few instances, frequencies in Supplementary Table S1 online differ from those published, as a result of errors identified during the curation and
review process. In some instances, authors were also contacted
for clarification or additional information to ensure that data
were captured accurately.
Genetics in medicine | Volume 19 | Number 1 | January 2017

Figure 2 CYP2D6 allele frequencies across world populations. The
graph depicts frequencies of no (no)-, decreased (↓)-, normal (↔)-, and
increased (↑)-function alleles that were calculated from studies reporting
a minimum of allelic variants (Supplementary Table S2 online columns
BF–BL). Allele frequencies represent the average of an allele in respective
populations and therefore do not add up to 100%. An accompanying
graph generated from all studies listed in Supplementary Table S2 online
(columns AL–AR) is provided as Supplementary Figure S1 online.

Although CYP2D6 allelic variation has been extensively studied in many populations, 42% of subjects are of European origin, followed by subjects who were East Asian (24%), from the
Americas (14%), African Americans (7%), from South Central
Asia (6%), from Africa (3%), from the Middle East (2%), and
from Oceania (1%) (calculated from Supplementary Table S2
online, column H).
Allele frequencies

The extent of genotype data varied considerably between studies
(Supplementary Table S1 online). Many contained information for a single allelic variant or a small number of allelic variants, whereas others were considerably more comprehensive or
utilized gene sequencing. To facilitate data summary, display,
and calculations, the most commonly genotyped allelic variants
and a selection of rare alleles often found only in some populations were extracted from Supplementary Tables S1 and S2
online. Allele frequencies are summarized for each study and by
major ethnicity and differences of allele frequencies across populations exemplified in Figure 1. For instance, the CYP2D6*10
decreased-function allele is lowest in Oceanians and Europeans
and highest in East Asians, averaging 1.6, 2.6, and 45%, respectively. By contrast, the no-function CYP2D6*4 allele is highest
in Ashkenazi Jewish and European subjects and lowest in East
Asian subjects, averaging 22, 18, and 0.6%, respectively.
As shown in Figure 2, allele frequencies across populations differed substantially when alleles were grouped as no-,
decreased-, normal-, and increased-function alleles. However,
71

AS, activity score; PM, IM, NM-S, NM-F, and UM, poor, intermediate, normal-slow, normal-fast, and ultrarapid metabolizer, respectively; the prefix “g” indicates genotype-predicted phenotype. p, q, r, and s, variables of the
Hardy Weinberg equilibrium. (See Supplementary Table S3 online).
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Phenotype frequencies are averages (in %) and were calculated from average allele-frequency data. A summary table including ranges (minimum and maximum) is provided in Supplementary Table S2 online (Summary tab).
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Table 1 Phenotype predictions from genotypes
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frequencies also varied depending on whether they were determined using all reports (Supplementary Figure S1 online) or
only those that genotyped for a minimum of allelic variants
(i.e., CYP2D6*2 and a minimum of no-function (*3, *4, *5) and
decreased-function (*10, *41) alleles). The latter differences are
caused mainly by (i) overestimation of CYP2D6*1 and/or *2
owing to limited genotyping that leads to CYP2D6*1 and/or *2
default assignments (depending on which SNPs/alleles were or
were not genotyped) and (ii) lack of data for no-, decreased-, and
increased-function alleles that have not been tested. To predict
phenotype as accurately as possible, only reports fulfilling the
aforementioned minimum genotype requirements were utilized
for phenotype predictions. Of the 263 entries (Supplementary
Table S2 online), 76—representing almost 20,000 subjects—
fulfilled these requirements. In this subset, 36% of subjects were
of European origin, followed by East Asians (29%), those from
the Americas (19%), African Americans (6%), Africans (3%),
South Central Asians (2%), Middle Easterners (3%), and those
from Oceania (1%) (calculated from Supplementary Table S2
online, column H).
Translation of genotype into phenotype

The Hardy-Weinberg equation (Supplementary Table S3
online) was used to determine the frequencies of diplotypes
from the frequencies of alleles grouped by their functionality
(Table 1) and an activity score (AS) assigned to each diplotype.
Figure 3a depicts the frequencies for all combinations of no-,
decreased-, normal-, and increased-function alleles. The allele
combinations gave rise to eight AS groups (AS = 0, AS = 0.5, AS
= 1, AS = 1.5, AS = 2, AS = 2.5, AS = 3, and AS = 4). Subjects
with AS = 0, AS = 0.5, and AS >2 were designated as genetic
poor, intermediate, and ultrarapid metabolizers (gPM, gIM, and
gUM), respectively. Subjects with AS = 1, AS = 1.5, and AS =
2 were designated as genetic normal metabolizers (gNM). (To
specify that the phenotype was predicted from the genotype, we
utilize the prefix “g,” as previously suggested.17) Because these
diplotype groups cover a wide range of activity, subjects with AS
= 1 are distinguished here as gNM-slow (gNM-S), and subjects
with AS = 1.5 and AS = 2 are designated as gNM-fast (gNM-F), in
accordance with the report by Gaedigk et al.14 Figure 3a,b shows
the frequencies of predicted phenotypes for AS groupings before
and after consolidating diplotype groups. Finally, Figure 3c
depicts the frequencies after consolidating AS = 1, 1.5, and 2 into
a single group of normal metabolizers (gNM).
Diplotype frequencies predicting poor metabolism were
highest in Europeans (average, 5.4%) and in the Ashkenazi
Jewish population (6%) and lowest in East Asians (average,
0.4), South Central Asians (average, 1%), Oceanians (average,
0.4), and subjects from the Middle East (average, 0.9) (Table 1,
Supplementary Table S2 online and Figure 3). On the other
end of the activity extreme, diplotypes predicting ultrarapid
metabolism were highest in Oceanian (21.2%), Ashkenazi Jewish
(11.5%), and Middle Eastern (11.2%) populations and lowest in
subjects from East Asia (1.4%). Considerable differences were
also observed for intermediate metabolizers (subjects with AS =
Volume 19 | Number 1 | January 2017 | Genetics in medicine
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Table 2 Comparison of predicted and observed poor
metabolizers
Ethnicitya
African
American

Subjects
phenotyped, n

Observed
frequency of
PMs (pPMs), %

Predicted frequency
of PMs (gPMs)b, %

1,200c

5.38

2.38

African

922c

2.57

2.78

From the
Americas

2,139

3.98

1.92

East Asian

906

0.84

0.41

European

7,757

8.45

5.44

None of the studies listed in Supplementary Table S2 online reporting
allele-frequency data for populations of the Middle East, Oceania, and South
Central Asia had phenotype data. bCalculated from studies meeting minimum
genotype requirements (Table 2 and Supplementary Table S2 online, column
BN). cSome subjects appear to be part of more than one investigation and are
reported on more than once.

a

0.5), ranging from 2.8% (from the Americas) to 11% (African
and African Americans). As discussed, there is no standard
approach to grouping, especially for AS groups 0.5 and 1.
A small subset of studies performed in vivo phenotyping in
addition to genotyping. The probe drug used to measure phenotype, number of subjects phenotyped, and frequencies of PMs
observed are indicated in Supplementary Table S2 online (columns BZ to CB) for each study. Table 2 summarizes observed
versus predicted frequencies for PMs. None of the reports for
the subjects from the Middle East, Oceania, or South Central
Asia had phenotype data. Phenotypic PMs are referred to here
as pPMs to distinguish them from genotype-predicted PMs
(gPMs). Papers reporting on phenotyping without accompanying genotype data were not included in this investigation. With
the exception of Africans, the frequency of pPMs was higher
than that predicted by genotype.

DISCUSSION

The materials provided by the CPIC guidelines,11–13 specifically
the CYP2D6 allele-frequency table (Supplementary Table S2
online), is a valuable resource (look-up table) regarding genetic
variation for a particular population or across major ethnic
groups. Because frequencies are tabulated for each study in a
standardized format, information regarding which variants
have been reported by each study and which variants were not
tested for is easy to retrieve. CPIC guidelines provide ample
information regarding allele frequencies and how to assign an
activity score and translate diplotypes into predicted phenotypes. In this report, we aimed to provide a comprehensive and
detailed summary of phenotypes predicted from genotype data.
Although we are providing results for major populations, the
compiled materials can be utilized for further, more detailed
population-specific/geographic-specific analyses by the reader.
Phenotype prediction from genotype data depends heavily
on the allelic variants present in a population of interest and
the alleles interrogated. Unless a study performs extensive
genotyping or uses a gene resequencing approach, many less
frequent, rare, and/or novel SNPs will elude detection and the
Genetics in medicine | Volume 19 | Number 1 | January 2017

frequencies of default alleles will be overestimated. For example, the CYP2D6*40 no-function allele defaults to CYP2D6*17,
a decreased-function allele, or normal-function CYP2D6*1 or
*2 designations if the key CYP2D6*2, *17, and/or *40 SNPs are
not part of the test panel. Because CYP2D6*1 and *2 are the
most common default assignments, their reported frequencies
vary widely between populations of similar ethnic backgrounds
and within the major ethnic groups (Supplementary Tables
S1 and S2 online). For instance, in Europeans, CYP2D6*1 and
*2 frequencies range from 29.2 to 100% (average, 63.1%; SD
±23.2) and from 10.5 and 40.6% (average, 27.8%; SD ±8.6). To
optimize the accuracy of phenotype prediction, we included in
our calculations only studies that tested for CYP2D6*2 and a
minimum of no-function (*3, *4, *5) and decreased-function
(*10, *41) alleles. Studies not meeting these criteria are likely
to miss a considerable number of no- and decreased-function
alleles and hence overestimate the normal-function CYP2D6*1
and *2 alleles. Only approximately one-third of the total number of studies and subjects tabulated fulfilled the minimal genotyping requirement. Some of the exclusions can be explained
by the time when a study was performed (before certain alleles
were known) or their focus on the determination of a single
allele of interest (e.g., that was discovered). The impact of the
amount of genotyping performed is evident in Figure 2. Similar
or higher frequencies of no- and decreased-function alleles and
lower frequencies of the CYP2D6*1 and *2 default alleles are
consistently detected for the subset of studies reporting data
for more inclusive allele panels. For African Americans, for
example, the frequency of no- and decreased-function alleles
increases from 9.7 and 26.3% to 15.4 and 36.3%, respectively,
whereas the frequency of CYP2D6*1 decreases from 75.9 to
46.6%. Although these differences are not as dramatic for all
major populations, similar trends are being observed (Figure 3
and Supplementary Table S2 online). Furthermore, our calculations do not include no- and decreased-function alleles for
which there is sparse information, are population-specific (e.g.,
CYP2D6*14, *15, *18 or *59, Supplementary Table S1 online),
or are technically difficult to genotype, such as CYP2D6*13-like
CYP2D7-2D6 hybrid arrangements,18,19 and are therefore typically not included in genotyping panels. There are also numerous allelic variants of unknown or uncertain in vivo function,
which may contribute to poor and/or intermediate metabolism.
Hence, phenotype predictions from genotype data on a population basis underestimate the prevalence of PM and IM subjects.
Additional challenges are grouping alleles into functional
categories and the resulting diplotypes into AS and phenotype
categories. As discussed by Hicks et al.,17 alleles are assigned a
value for classification (no, decreased, normal, and increased
function) to determine the AS of a diplotype,6,14 but this
rather crude system does not take into account the degree of
decreased or increased function or substrate-specific activity of
an allele. We classified CY2D6 *2 as a functional allele, which
is consistent with its classification in CPIC guidelines11–13 and
our findings with atomoxetine as described here. However,
this or other alleles may need to be assigned a different value
73
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Figure 3 CYP2D6 phenotype prediction from genotype data. An activity score (AS) was assigned to each genotype (no, ↓, ↔, and ↑ indicate genotypes
with no-, decreased-, normal-, and/or increased-function allele combinations). Panel a shows average frequencies for the different allele combinations and their
respective phenotype classifications into poor (gPM), intermediate (gIM), normal-slow (gNM-S), normal-fast (gNM-F), and ultrarapid (gUM) metabolizer groups.
The prefix “g” indicates that the phenotype is predicted from genotype. For panel b, genotypes giving rise to AS = 1 or AS = 2 were grouped as indicated.
Panel c depicts the translation of genotype or AS into phenotype according to the classification used in CPIC guidelines. Note that genotypes falling into the
AS = 1 group are inconsistently classified as gIM or gNM throughout the literature.

to more accurately reflect their activity toward a particular
drug,20 which may lead to different phenotype classifications
of some diplotypes and shift population profiles. In our recent
study investigating the norepinephrine reuptake inhibitor atomoxetine, subjects with an AS of 0.5 presented with a total
74

atomoxetine systemic exposure that was significantly different
from that observed for subjects with an AS of 1 or 2 (ref. 21)
Differences in the pharmacokinetics of atomoxetine have also
been observed between groups with an AS of 1, 1.5, and 2 in
East Asian subjects.22,23 Based on these findings, classification of
Volume 19 | Number 1 | January 2017 | Genetics in medicine
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subjects with AS of 0.5 as IMs and those with AS of 1, 1.5, or 2
as NMs can be justified for atomoxetine. For other substrates,
however, allele values may need to be revised to reflect their
activity toward the substrate of interest. The provided worksheets enable the reader to easily reclassify an allele of interest
from, for example, functional to decreased function, and recalculate phenotype frequencies.
In general, there is a consensus on defining subjects with
two no-function alleles (AS = 0) as gPMs and those with one
decreased-function (AS = 0.5) or two (AS = 2) or three or more
functional gene copies (AS ≥ 3) as gIMs, gNM, and gUMs,
respectively. However, some investigators define diplotypes
with an AS of 0 or 0.5 as poor or slow metabolizers. Subjects
with AS of 1 and 1.5 diplotypes are the most controversial and
are grouped as either gIMs or gNM. Likewise, diplotypes with
an AS of 2.5 may be grouped as gNMs or gUMs. Although arguments can be made for and against groupings, especially when
pharmacokinetic data are lacking or sparse, in the absence of
standardization it can be difficult (if not impossible) to interpret results, compare reports, or draw definitive conclusions.24
This is further exaggerated if reports do not clearly describe
grouping procedures and/or variants genotyped. As illustrated
in Figure 3, the notable differences in frequencies of IMs and
NMs, depending on grouping, underscore the importance of
full disclosure of how genotype is translated into phenotype
and probably also explain discordant findings in the literature
comparing genotype with phenotype associations.
LLerena et al.8 analyzed interethnic variability of CYP2D6
alleles and compared predicted and measured phenotypes across
world populations. Data were extracted from 172 articles that
encompassed 44,572 individuals. The authors reported allele frequencies for CYP2D6*4, *10, *17, *29, and *41 that are similar
to the frequencies we have determined for African Americans,
East Asians, and Europeans. Those for Middle Easterners differ,
which is probably due to the inclusion of additional data into
our analysis. For other ethnic groups, comparisons of findings
are difficult to make, mostly because of differences in grouping.
Regarding phenotype, LLerena et al. focused on comparing predicted and measured phenotypes for PMs and UMs. To that end,
these authors included phenotype studies that did not include
genotype data. With few exceptions, the frequency of phenotypic
PMs (referred to by LLerena et al. as mPM, “metabolic” phenotype and corresponding to the term “phenotypic” PMs (pPMs)
used in this report) was higher than that predicted by genotype,
which is in line with our findings (Table 2). For example, LLerena
et al. found predicted (gPM) versus observed (pPM) frequencies
of 5.75 vs. 7.08%, 6.32 vs. 8.13%, and 0.26 vs. 0.84% for Caucasian
Americans, Central Europeans, and East Asians, respectively.
Corresponding observations from our study were 5.44 vs. 8.45%
and 0.41 vs. 0.84% for Europeans and East Asians, respectively.
Considering that genotyping does not detect all no-function
alleles, and that our analysis did not take into account rare alleles
if data were available in only a single report or a few reports, it
is not surprising that the frequency of predicted PMs is lower
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than that of observed PMs. Similarly, the frequency of gIMs
(i.e., subjects with AS = 0.5 diplotypes consisting of one noand one decreased-function allele) is probably underestimated
and the frequency of gUMs may be overestimated if the presence of a duplication event is defaulted to a CYP2D6*2xN (i.e.,
a duplication or multiplication of a normal-function allele).6,18,25
Although undetected and unknown allelic variants account for a
portion of the difference between predicted and observed phenotypes, other genetic factors such as a recently described distant enhancer SNP expression26,27 and variations in the gene of
the nuclear factor 4 alpha transcription factor28,29 have also been
shown to impact CYP2D6 gene expression, and thus activity, and
are currently not factored into phenotype prediction algorithms.
Genetic variation in POR could also contribute to variability in
observed cytochrome P450 oxidoreductase (CYP2D6) activity.30 Furthermore, inhibition of CYP2D6 enzymatic activity by
concomitant medication(s) can dramatically change a person’s
metabolic capacity presenting with a phenotype that does not
match with the genetic phenotype.20,31,32 There is also growing
evidence that transient or chronic conditions such as pregnancy
and inflammation can alter the activity of drug-metabolizing
enzymes including CYP2D6 that may lead to phenocopying.33–36
The implication of phenocopying for genotype–phenotype association studies has been reviewed by Shah et al.,37 and the impact
of physiological, pathological, and environmental factors on
CYP2D6 expression and activity and their implications for precision medicine have been reviewed by He et al.3
The accuracy of actionable CYP2D6 phenotypes prediction by
genetic analysis could be further improved by extending allele
coverage of test panels or utilizing sequence-based approaches
such as those recently described38,39 and complement such efforts
with gene copy-number-variation analysis capable of determining gene copy number, allelic variation of the copied/multiplied
gene copies, and rearranged gene structures. However, even
the most advanced genetic test strategy will have its limitations
unless other factors are integrated, including genetic variation
in other loci contributing to the transport, metabolism, and
disposition of a substrate/drug of interest, allele/drug-specific
metabolism, and host factors such as comedication and underlying physiological and pathological conditions.
In summary, we present CYP2D6 phenotype predictions based
on the most comprehensive, literature-based, allele-frequency
compilation available. Data are presented for each included
report, making the provided materials a highly valuable resource
for allele-frequency distributions and phenotype predictions
across and between populations. Interpretation of the functional
consequences of predicted phenotypes for drug clearance in vivo,
and thus translation into specific dosing guidelines for individual
drug–diplotype pairs, will benefit from future genotype-stratified
pharmacokinetic studies for high-priority drugs.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper
at http://www.nature.com/gim
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